Aytu BioPharma Inc(AYTU) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:00 PM ET (Korea 10/27 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.67 | Insider Own | 8.26% | Shs Outstand | 10.7M | Perf Week | -1.53% |
| Market Cap | 0.02B | Forward P/E | 7.15 | EPS next Y | 143.32% | Insider Trans | - | Shs Float | 10.0M | Perf Month | -15.35% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.26 | Inst Own | 35.3% | Short Float | 3.46% | Perf Quarter | -9.39% |
| Income | -0.01B | P/S | 0.36 | EPS this Y | 46.26% | Inst Trans | -4.64% | Short Ratio | 9.91 | Perf Half Y | -24.61% |
| Sales | 0.06B | P/B | 0.59 | EPS next 5Y | - | ROA | -12.41% | Short Interest | 0.35M | Perf YTD | -25.77% |
| Book/sh | 3.29 | P/C | 0.8 | EPS past 3/5Y | 39.03% 55.93% | ROE | -52.55% | 52W High | -37.03% ($3.07) | Perf Year | -14.98% |
| Cash/sh | 2.42 | P/FCF | 6.46 | Sales past 3/5Y | -18.77% -2.59% | ROIC | -31.51% | 52W Low | 7.22% ($1.80) | Perf 3Y | -33.68% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 27.11% | Gross Margin | 59.62% | Volatility(W/M) | 4.43% 4.35% | Perf 5Y | -95.95% |
| Dividend TTM | - | EV/Sales | 0.22 | Sales Y/Y TTM | -13.27% | Oper. Margin | -12.57% | ATR (14) | 0.1 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 1 | EPS Q/Q | 99.97% | Profit Margin | -24.76% | RSI (14) | 39.92 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.13 | Sales Q/Q | 6.42% | SMA20 | -4.49% ($2.02) | Beta | 0.24 | Target Price | $9.67 |
| Payout | - | Debt/Eq | 0.51 | Earnings | 2026/9/22 | SMA50 | -9.59% ($2.13) | Rel Volume | 0.48 | Prev Close | $1.9 |
| Employees | 76 | LT Debt/Eq | 0.28 | EPS/Sales Surpr. | 100% 31.2% | SMA200 | -17.22% ($2.33) | Avg Volume(3M) | 0.03M | Price | $1.93 |
| IPO | 2008/9/24 | Option/Short | No/Yes | Trades | 119 | Volume | 16,560 | Change | 1.58% |
A U.S. commercial-stage specialty pharmaceutical company that sells ADHD treatments Adzenys and Cotempla, pediatric prescription medications Karbinal and Poly-Vi-Flor, and is advancing the commercialization of EXXUA, a treatment for major depressive disorder (MDD).
Over the past 1 year, on the lower side
37% below its 1-year high.
Traded less than usual. That is 48% of its average volume.
AYTU has weak earning power
Of every $100 in sales, $12.57 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +46.3% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $36. Peers typically go for $197.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 35.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
DCOR US Core Equity 1 Portfolio ETF Class Shares <0.01% 
DFAC U.S. Core Equity 2 Portfolio-ETF Class Shares <0.01% 
DFAS U.S. Small Cap Portfolio-ETF Class Shares <0.01% 
DFSU Dimensional US Sustainability Core 1 ETF <0.01% 
VTI Vanguard Morningstar Total Stock Market ETF <0.01% It ranks #68 of 83 in the industry
Based on market cap of $21M.
FAQ
What kind of company is AYTU?
AYTU belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of AYTU?
The market cap of AYTU is approximately $21M, ranking 5,196 within its sector.
What is the 52-week high and low for AYTU?
AYTU has recorded a 52-week high of $3.07 and a low of $1.80.
